On October 9, 2026, Scanvio Medical AG, an ETH Zurich spin-off, announced that its software Scanvio Assist has received CE marking as a Class IIa medical device software under the EU Medical Device Regulation (EU MDR 2017/745), after a conformity assessment by notified body TÜV SÜD (NB 2443). The company says that, to its knowledge, this is the world's first CE-marked AI-assisted ultrasound technology built specifically to help clinicians identify signs of endometriosis. The certification lets Scanvio start clinical use across Europe.

Why It Matters

Endometriosis is one of femtech's largest unmet diagnostic needs and is directly tied to sexual health: painful sex (dyspareunia) is a hallmark symptom, and the condition is a major cause of infertility. Long diagnostic delays mean years of untreated pain, missed fertility windows, and a patient group that sexual-wellness, pelvic-health and fertility companies struggle to reach because there's no diagnosis to route through. An AI layer that brings general gynecologists closer to specialist-level scanning could move diagnosis earlier and toward non-invasive imaging, which would grow the pool of diagnosed patients that downstream pain management, pelvic-floor and fertility products depend on. For investors, the software-on-existing-hardware model and the OEM add-on route are the scalable part. The open questions are published accuracy data and whether reimbursement follows.

The product is software, not a scanner. Scanvio Assist runs on existing ultrasound equipment and gives real-time AI support during transvaginal ultrasound, fitting into the normal exam workflow. The problem it targets: ultrasound can show signs of endometriosis, but "examination quality depends heavily on clinical expertise," and specialist sonographers are scarce. That scarcity helps explain why diagnosis so often depends on laparoscopy and takes years. Citing the WHO, Scanvio puts prevalence at roughly 10% of women of reproductive age, about 190 million people.

Commercially, Scanvio says it is now onboarding its first gynecologists, fertility clinics and endometriosis centers in Europe. It is also pitching ultrasound manufacturers on integrating Scanvio Assist as a software add-on, a licensing route that could get it into installed equipment faster than selling clinic by clinic. CEO and co-founder Dr. Stefan Tuchschmid said the team spent "the past years developing and validating this technology together with clinicians" and now wants to "put it into the hands of gynecologists and sonographers." Startupticker's company record shows Scanvio raised $3.4M in July 2025 to pursue earlier endometriosis diagnosis. Neither release includes clinical performance figures such as sensitivity or specificity. Those are the numbers clinicians and payers will look for first.

Sources

Update — 2026-10-11

Initial entry — story first created.